Lilly's 13 acquisitions in 2026, worth about $32B, are recycling cash back to at least 50 biotech venture investors.
Trump strikes MFN drug-pricing deals with 9 more drugmakers as Incyte joins quietly; Oz says 600K seniors signed up for CMS ...
Alumis' lupus drug misses its Phase 2b goal, sending shares down over 50%, but a high-IFNGS subgroup shows a path toward ...
Google's Gemini now lets users book appointments via Zocdoc. Google Health Chief Michael Howell and Zocdoc CEO Oliver Kharraz ...
Roche licenses Simcere Zaiming's preclinical trispecific T cell engager SIM0660 for $75M upfront, up to $1.53B in biobucks, its second China biotech deal this month.
Novartis halts CAR-T trials after three patient deaths from an immune overreaction; Bristol Myers pauses zola-cel enrollment.
Eli Lilly acquires Merida Biosciences for up to $2.875B, gaining MER511 for thyroid eye disease/Graves' disease and MER769 ...
Sanofi-backed Electra files for a Nasdaq IPO to fund Phase 2/3 trials of ipsoprubart, its lead antibody for the rare disease ...
ARCH Venture Partners is targeting $3B for its 14th fund, per an SEC filing, matching the size of the fund it disclosed in ...
Nine more drugmakers strike voluntary drug-pricing deals with the White House, pledging nearly $20B in US investments to avoid tariffs and CMS pricing pilots.
CRISPR Therapeutics’ gene editing candidate showed mixed durability results a year after patients were dosed, according to ...
FDA approves Roivant's Lisraya (brepocitinib), first oral drug for dermatomyositis; TD Cowen sees $5B–$10B potential across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results